Aspira Women’s Health signed a deal with Cleveland Clinic to expand access to patient samples and accelerate the clinical validation of multiomic diagnostics in women’s health. The collaboration is designed to support more robust biomarker discovery and translation. By building sample access and validation pathways with a major clinical provider, Aspira aims to tighten the loop between discovery signals and the evidentiary requirements needed for diagnostic performance. Multiomic approaches typically combine molecular layers (such as proteomic and genomic features) to improve specificity over single-marker strategies. For industry participants, the agreement highlights how diagnostics companies are partnering with health systems to de-risk analytic and clinical validation stages—an area where longitudinal sample quality and standardized collection are often the bottlenecks. The near-term impact will depend on the specific cohorts enrolled, the biomarker panels evaluated, and whether the platform demonstrates clinically meaningful sensitivity and specificity in prospective validation.